Pharmaceuticals II: The Hidden Engines of Medicine — CDMOs 🧪⚙️

let’s dive into one of its most fascinating gears: Contract Development and Manufacturing Organisations (CDMOs) — the silent powerhouses behind the medicines you take but rarely see. 💊🤫 CDMOs? They’re the expert kitchens that bring those recipes to life, whipping up complex ingredients (APIs), formulations, and high-tech injectables — all without putting their own name on the dish. 👩‍🔬🏭 Why do big pharma companies love CDMOs? Because outsourcing production means they can focus on creating new drugs, while CDMOs handle the tough, regulated manufacturing process. It’s no simple factory job — from lab to large-scale production, it takes precision, trust, and years of proving you can deliver. ⏳✅ India’s shining stars in this story are

and Divi’s doesn’t launch medicines, About 55% of its revenue comes from custom synthesis — crafting complex building blocks for patented drugs 🧬. The rest comes from making generic APIs sold worldwide. Recently, Divi’s sealed a multi-year deal for an “advanced intermediate” — a sign that top global pharma trusts them deeply 🤝. They’re also betting big on peptides — exciting molecules behind popular new therapies like Ozempic 💉 and quietly growing in contrast media used in medical imaging 🩻. While Divi’s conquers the world, Akums rules India’s local pharma scene, making medicines for hundreds of Indian brands 🏥💊. With 11 plants and 60+ dosage forms, Akums handles everything from tablets to complex injectables. it co-develops drugs, files regulatory paperwork, and innovates niche formulations, giving it pricing power beyond the usual 💼💡. Though API price swings keep revenues volatile, Akums is expanding into Europe with a big contract, signaling global ambitions 🌐🚀. This quarter showed volume growth 📈 but margin pressure due to a shift toward lower-margin products and seasonal costs — nothing structural, just the nature of the business 🏃‍♂️💸.